Get to know our clinical trials
Phase I clinical trial to investigate subcutaneous rilvegostomig in adult participants with advanced solid tumors who have previously received treatment.
THE PRIMARY OBJECTIVE IS TO DETERMINE THE PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) RILVEGOSTOMIG COMPARED TO INTRAVENOUS (IV) RILVEGOSTOMIG 750 MG EVERY 3 WEEKS (Q3W).
Technical Summary
- PHASE I, MULTICENTER, DOSE-FINDING AND CONFIRMATION STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS RILVEGOSTOMIG IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS WHO HAVE PREVIOUSLY RECEIVED THE REFERENCE TREATMENT (ARTEMIDE SUBQ).
- Code EudraCT: 2025-521614-26-00
- Protocol number: D702EC00001
- Promoter: Astrazeneca
- Molecule/Drug: Rilvegostomig
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.